Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Revelation Biosciences Inc (REVB)

Revelation Biosciences Inc (REVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress Business Wire - Thu Mar 30, 2023

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment...

REVB : 0.8480 (+3.04%)
Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board Business Wire - Mon Mar 13, 2023

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment...

REVB : 0.8480 (+3.04%)
Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference Business Wire - Mon Mar 6, 2023

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment...

REVB : 0.8480 (+3.04%)
Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering Business Wire - Mon Feb 13, 2023

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention...

REVB : 0.8480 (+3.04%)
Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering Business Wire - Thu Feb 9, 2023

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention...

REVB : 0.8480 (+3.04%)
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300 Business Wire - Tue Feb 7, 2023

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) announced today statistically significant results in a validated preclinical model of acute and chronic kidney disease....

REVB : 0.8480 (+3.04%)
Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders Business Wire - Tue Jan 31, 2023

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) announced today that, on February 1, 2023, the Company will implement a 1-for-35 reverse split of its common stock following...

REVB : 0.8480 (+3.04%)
Revelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023 Business Wire - Tue Jan 10, 2023

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 13, 2023, the Company’s units, which trade with the ticker symbol “REVBU” will...

REVB : 0.8480 (+3.04%)
Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model Business Wire - Fri Nov 18, 2022

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment...

REVB : 0.8480 (+3.04%)
Revelation Biosciences Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Recent Corporate Progress Business Wire - Thu Nov 10, 2022

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment...

REVB : 0.8480 (+3.04%)

Barchart Exclusives

Panic (Buying) in the Streets of London: Here's the 1 Stock Set to Benefit Barchart - 1 hour ago
The blocking of bauxite exports from Guinea is the latest news to send alumina prices skyrocketing, with much of the panic buying coming from China, the world's biggest aluminum producer. Prices hit a record high last week, surpassing levels last seen in 2018, when the U.S. placed sanctions on Russia’s Rusal. One company poised to benefit is Alcoa. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot